Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS) — Stella

Home/Mild Autonomous Cortisol Secretion/

View on ClinicalTrials.gov

Recruiting

Back to Mild Autonomous Cortisol Secretion trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Mayo Clinic, Rochester, Minnesota

Key details

Phase

Safety & dosing

Sponsor

Mayo Clinic

Collaborators

RECORDATI GROUP

Enrollment target

~15 participants

Started

January 2026

Primary completion

January 2027

Age range

18 Years and older

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.